Thrombolytic therapy myocardial infarction assessment efficacy myocardial perfusion sestamibi sestamibi efficacy thrombolytic therapy image quality due photon energy allowable doses radiopharmaceutical along lack redistribution sestamibi acceptable imaging agent studies imaging agent serial quantitative planar tomographic imaging initial risk area infarction change time relation infarct-related artery patency patients first acute myocardial infarction patients recombinant tissue-type plasminogen activator rt-PA hours onset acute chest pain patients conventional manner thrombolytic therapy initial area risk patients rt-PA conventional therapy Patients successful thrombolysis patient infarct arteries reduction sestamibi defect size patients persistent coronary occlusion Serial sestamibi important application future clinical research efficacy new thrombolytic agents Direct measurements amount hypoperfused myocardium thrombolysis rapid unequivocal results patients use mortality end point approach clinical arena 